APA (7th ed.) Citation

Y, L., XY, Z., WS, W., RQ, L., QW, P., YJ, Z., . . . LR, H. (2026). Stereotactic body radiotherapy plus sunitinib vs. sunitinib alone in treatment-naive oligometastatic renal cell carcinoma: A phase 2 clinical trial. Cell reports. Medicine, 7(5), 102747. https://doi.org/10.1016/j.xcrm.2026.102747

Chicago Style (17th ed.) Citation

Y, Liu, et al. "Stereotactic Body Radiotherapy Plus Sunitinib Vs. Sunitinib Alone in Treatment-naive Oligometastatic Renal Cell Carcinoma: A Phase 2 Clinical Trial." Cell Reports. Medicine 7, no. 5 (2026): 102747. https://doi.org/10.1016/j.xcrm.2026.102747.

MLA (9th ed.) Citation

Y, Liu, et al. "Stereotactic Body Radiotherapy Plus Sunitinib Vs. Sunitinib Alone in Treatment-naive Oligometastatic Renal Cell Carcinoma: A Phase 2 Clinical Trial." Cell Reports. Medicine, vol. 7, no. 5, 2026, p. 102747, https://doi.org/10.1016/j.xcrm.2026.102747.